(600079)"Humanwell Healthcare (Group) Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600079 · · 17 pages · Chinese
Summary by 6ix AI
The report confirms that the financial data has not been audited and includes key figures such as revenue and net profit. The company reported significant increases in both total profit and net profit attributable to shareholders compared to the same period last year. Additionally, the report outlines the company's total assets and shareholders' equity at the end of the quarter, showing growth from the previous year.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Humanwell Healthcare (Group) Co.,Ltd. on 6ix
Earlier from Humanwell Healthcare (Group) Co.,Ltd
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the U.S. FDA Approval Number for Lubiprostone Soft Capsules
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the Marketing Authorization for Sugammadex Sodium Injection from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the US FDA Approval Number for Diltiazem Hydrochloride Tablets
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on Disclosure of Proposal for 2026 Private Placement of A-Shares (Second Revised Draft)
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the Private Placement of A-Shares (Second Revised Draft)
Later from Humanwell Healthcare (Group) Co.,Ltd
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Approval of Registration for Super Short-term Commercial Paper
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining Marketing Authorization for Fentanyl Citrate Injection from the German Federal Institute for Drugs and Medical Devices (BfArM)
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice for HW281171 Tablets
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice for Midazolam Nasal Spray
- (600079)"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on Acceptance of Application of the Subsidiary for Drug Marketing Authorization
Follow Humanwell Healthcare (Group) Co.,Ltd into a list and get an email when it puts out news.
Follow Humanwell Healthcare (Group) Co.,Ltd